anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A computer-implemented system for controlling the condition of a biological sample, comprises a computer-based resource arranged to transmit configuration data to a sensor associated with the biological sample. The configuration data specifies an acceptable value or range of values, such as a threshold value, for an environmental factor relating to the biological sample e.g. geographical location or temperature. The sensor may repeatedly send data relating to the environmental factor to the computer-based resource. Alternatively, the sensor may be arranged to start recording and/or transmitting data relating to the environmental factor: (i) after the sensor has been configured; and/or (ii) after a specified period of time or at a specified time; (iii) upon detection of a pre-determined condition. Deviation of the environmental data from an acceptable range of values may result in an alarm or alert notification being generated. The sensor may be arranged to delay operation until a specified time period has elapsed, or until a certain condition is met e.g. the temperature of the sample has stabilised. The system may allow real-time monitoring of the biological sample. The biological sample may be stem cells, bone marrow, blood or tissue.
This study was a randomized, single-blind, single-center, positive drug controlled, non-inferiority trial. According to the inclusion and exclusion criteria, 126 patients undergoing general anesthesia for elective non-cardiac surgery in Beijing Chaoyang Hospital were selected. In the intervention group, anesthesia was induced with remimazolam besylate at a rate of 6mg/min; Anesthesia was maintained with 1.0-2.0mg/min remimazolam besylate by continuous pump. Control group: anesthesia induction, intravenous injection of propofol 2mg/kg; Anesthesia was maintained by continuous pumping of 6-8mg/kg/h propofol. All patients were routinely monitored for vital signs and anesthesia depth after entering the operating room. After the patient lost consciousness, routine analgesia and muscle relaxants were given, followed by tracheal intubation and mechanical ventilation. During the anesthesia maintenance phase, vital signs and depth of anesthesia were continuously monitored, sedatives and analgesics were continuously pumped, and muscle relaxants were added intermittently as needed. The patients were followed up after surgery, and the quality of recovery score at 24 hours after surgery was the main study outcome.
One patient with advanced solid cancer will receive 3 hyperthermia treatments of 4 hours per treatment. The next patient with advanced solid cancer will receive 3 hyperthermia treatments of 6 hours per treatment.
INTRODUCTION: Delayed bleeding is a potentially serious complication after partial nephrectomy (PN), with reported rates of 1%-2%. Patients with multiple renal tumors, including those with hereditary forms of kidney cancer, are often managed with resection of multiple tumors in a single kidney which may increase the risk of delayed bleeding, though outcomes have not previously been reported specifically in this population. The objective of this study was to evaluate the incidence and timing of delayed bleeding as well as the impact of intervention on renal functional outcomes in a cohort primarily made up of patients at risk for bilateral, multifocal renal tumors.
METHODS: A retrospective review of a prospectively maintained database of patients with known or suspected predisposition to bilateral, multifocal renal tumors who underwent PN from 2003 to 2023 was conducted. Patients who presented with delayed bleeding were identified. Patients with delayed bleeding were compared to those without. Comparative statistics and univariate logistic regression were used to determine potential risk factors for delayed bleeding.
RESULTS: A total of 1256 PN were performed during the study period. Angiographic evidence of pseudoaneurysm, AV fistula and/or extravasation occurred in 24 cases (1.9%). Of these, 21 were symptomatic presenting with gross hematuria in 13 (54.2%), decreasing hemoglobin in 4(16.7%), flank pain in 2(8.3%), and mental status change in 2 (8.3%), while 3 patients were asymptomatic. Median number of resected tumors was 5 (IQR 2-8). All patients underwent angiogram with super-selective embolization. Median time to bleed event was 13.5 days (IQR 7-22). Factors associated with delayed bleeding included open approach (OR 2.2, IQR(1.06-5.46), P = 0.04 and left-sided surgery (OR 4.93, IQR(1.67-14.5), P = 0.004. Selective embolization had little impact on ultimate renal functional outcomes, with a median change of 11% from the baseline eGFR after partial nephrectomy and embolization. One patient required total nephrectomy for refractory bleeding after embolization.
CONCLUSIONS: Delayed bleeding after PN in a cohort of patients with multifocal tumors is an infrequent event, with similar rates to single tumor series. Patients should be counseled regarding timing and symptoms of delayed bleeding and multidisciplinary management with interventional radiology is critical for timely diagnosis and treatment.
Somatostatin analogs are prepared wherein a cyclic hexapeptide contains a secondary amino acid which replaces seven of the ring amino acids of somatostatin. The cyclic hexapeptides are easier to synthesize, have a longer duration of activity, and many have a greater level of activity than somatostatin. The compounds have the properties of inhibiting the release of glucagon, growth hormone and insulin. Certain of the compounds also are capable of inhibiting the release of gastric acid secretions. The compounds are particularly useful in the treatment of acromegaly, diabetes, diabetic retinopathy and peptic ulcers. These cyclic hexapeptides are prepared by the solid phase method.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine and can be used for treatment of deep stromal keratites. Treatment is resalised by traditional pharmacotherapy, including specific antiviral and/or antibacterial medications, non-steroid anti-inflammatory and anti-allergic medications, as well as keratoprotectors. Additionally into layer of ill eye corneal stroma around pathologic nidus introduced are 0.5 ml of cell suspension, containing autologous mononuclear cells (AM). Suspension is introduced immediately after its preparation. For this purpose AM are isolated from heparinised patient's blood by method of fractioning in density gradient on separating ficoll-verografin solution with ratio of gradient and separated suspension volumes 1:3-1:4, at 2000 rev/min, at room temperature during 15 minutes. After that, 1.0 ml of isotonic sodium chloride solution is added and obtained suspension is re-centrifuged during 7 minutes at 1500 rev/min. Then, obtained cell suspension is placed into sterile vial with addition of 3.0 ml of isotonic sodium chloride solution and is used for introduction into cornea stromal layer. In the process of treatment procedure is repeated 1-2 times with 4-6 day interval depending on disease severity degree and clinical picture dynamics. ^ EFFECT: method ensures elimination of corneal syndrome, disappearance of cornea edema, resorption of necrotic masses, cornea epithelisation and increase of visual acuity, thus reducing treatment terms and number of disease complications. ^ 1 ex, 1 tbl
The project will conduct a randomized control trial (RCT) of an innovative program for people experiencing homelessness (PEH) that initially designed to address social isolation and loneliness among people experiencing homelessness but subsequently paired with an economic poverty-reduction intervention. The social support intervention, known as "Miracle Friends (MF)," pairs an unhoused person with a volunteer "phone buddy." The poverty reduction intervention, known as "Miracle Money (M$)," provides guaranteed basic income of $750 per month for 1 year to MF participants. The RCT will have 3 arms of PEH who expressed interest in the phone buddy program: (1) those assigned to Miracle Friends; (2) those assigned to Miracle Money, which is not disclosed until after they actively engage in the Miracle Friends program; (3) And those assigned to a waitlist for Miracle Friends. To recruit for the study, the Miracle Friends program engage PEH through a variety of homeless services partners and introduce the MF program. Anyone who is interested in the MF program is provided information about a 15-month longitudinal study and referred to the research team to complete an eligibility screener. The research team explains the interview protocols that include receiving a $30 incentive each time a survey is completed that includes a baseline and 5 quarterly surveys. Participants will also be notified about being randomly selected to either be offered MF or put on a waitlist. Those assigned to the M$ are not notified about receiving monthly income until after they engage in the MF program. Information about frequency of contact with the MF social support volunteer and volunteer demographics will be provided directly from the Miracle Friends administrative data records.
BACKGROUND: To identify the factors influencing the early encapsulation of peripancreatic fluid/necrosis collections via contrast-enhanced computed tomography (CECT) and to determine the clinical significance of early encapsulation for determining the prognosis of acute pancreatitis (AP) patients.
METHODS: AP patients who underwent CECT between 4 and 10 days after disease onset were enrolled in this study. Early encapsulation was defined as a continuous enhancing wall around peripancreatic fluid/necrosis collections on CECT. Univariate and multivariate logistic regression analyses were performed to assess the associations between the variables and early encapsulation. Clinical outcomes were compared between the non-encapsulation and early encapsulation groups with 1:1 propensity score matching.
RESULTS: A total of 289 AP patients were enrolled. The intra-observer and inter-observer agreement were considered good (kappa statistics of 0.729 and 0.614, respectively) for identifying early encapsulation on CECT. The ratio of encapsulation increased with time, with a ratio of 12.5% on day 5 to 48.7% on day 9. Multivariate logistic regression analysis revealed that the longer time from onset to CECT examination (OR 1.55, 95% CI 1.23-1.97), high alanine aminotransferase level (OR 0.98, 95% CI 0.97-0.99), and high APACHE II score (OR 0.89, 95% CI 0.81-0.98) were found to be independent factors associated with delayed encapsulation. The incidence of persistent organ failure was significantly lower in the early encapsulation group after matching (22.4% vs 6.1%, p = 0.043). However, there was no difference in the incidence of infected pancreatic necrosis, surgical intervention, or in-hospital mortality.
CONCLUSIONS: AP patients without early encapsulation of peripancreatic fluid/necrosis collections have a greater risk of persistent organ failure. In addition to longer time, the high APACHE II score and elevated alanine aminotransferase level are factors associated with delayed encapsulation.
The objective of this study is to formulate and implement graded biological models pertaining to binocular visual perception function with the use of computer algorithms. We aim to quantitatively assess the location, severity, and degree of impairment in binocular visual perception among patients who have suffered stroke, thereby providing valuable insights into the repercussions of cerebral tissue damage on the visual system. To overcome the shortcomings of previous instruments used to assess binocular function in terms of stereoscopic effects and the challenges posed by physiological and psychological interference during examinations, this study optimized its approach by integrating polarized stereovision technology with computer graphic modeling techniques. This study employed computer models to assess binocular visual perception function in stroke patients. Computer models refer to psychophysical testing methods used to measure binocular visual perception function, including various assessment tasks such as recognizing inverted letters and assessing stereopsis during high-speed movements. The cross-into-circle test was used as a means to quantify perceptual eye position. Subsequently, the collected data was analyzed to assess the magnitude of impairment in binocular visual perception. The results of the study revealed a spectrum of binocular visual perception impairment among patients diagnosed with stroke, demonstrating discernible variations in the recognition of inverted letters and stereopsis across different movement speeds. Importantly, perceptual eye position measurements offered valuable insights into ocular misalignment. The computational models effectively quantified both the spatial distribution and severity of these identified impairments. Damage to brain tissue resulting from a stroke can give rise to notable impairments in binocular visual perception function. Graded biological models, formulated through computer algorithms, provide a systematic framework for the comprehensive evaluation and quantification of these impairments. The comprehension of the nature and extent of visual impairments observed in patients with stroke establishes a basis for the development of personalized visual perception learning methodologies. Based on such tailored approaches, we aim to facilitate the recovery of impaired visual function, thereby contributing to the broader objective of neural system rehabilitation.
All subjects will receive White Light Imaging (WLI) and Lugol's Chromoendoscopy (LCE), the current standard of care (SOC) procedure. Following LCE, all subjects will receive the artificial intelligence (AI) mobile high-resolution microendoscopy (mHRME) imaging with Proflavine Hemisulfate of any LCE abnormal and LCE normal areas (4:1 ratio). For both WLI and LCE, we will record the subjective clinician read (neoplastic, non-neoplastic), the confidence level in their diagnoses (high, low), and the action plan (biopsy vs. no biopsy vs. treat). With the AI-mHRME, we will image the same LCE abnormal and normal areas and record the software read, the clinician confidence level, and action plan. Finally, the imaged LCE abnormal areas will be biopsied or resected, and evaluated by a pathologist.
1. Technical Result Improvement of medicinal and prophylactic properties of food additive by enriching it with biologically active agents and widening of assortment. 2. Essence A food additive in mass % comprises dried spirit extracts of 10-15 buckhorn plantain, 10-15 nettle, 10-15 hips, 5-10 tea fruit and the rest – fresh tealeaves. A method comprises extracting each plant raw comprised in food additive separately, at least by 70% spirit, after which they are dried and stirred. 3. Field of Application Food industry.
This systematic review synthesized the literature on digital health interventions for the promotion of physical activity (PA) among people with intellectual disabilities and/or autism. From an initial screening of 553 records, 10 studies underwent full-text review. Data were extracted relating to study, intervention, and sample characteristics and PA-related findings. Methodological quality was evaluated using the Crowe Critical Appraisal Tool. There were mixed findings pertaining to the effectiveness of digital health interventions for promoting PA among these populations. Positive results were reported for three of five active-video-game interventions, two of three social-media-based interventions, and one of two e-learning/multicomponent interventions. Digital health interventions can potentially be effective for promoting PA among people with intellectual disabilities and/or autism. However, the large variation in the samples and intervention types and a reliance on pre- and quasi-experimental research designs suggest that inferences should be made with caution and additional research is needed.
PROBLEM TO BE SOLVED: To obtain an antibacterial agent for oral cavity and composition formulates therewith, manifesting specifically an antibacterial activity to a causing bacterium for periodontosis by formulating a specific material obtained by a strain of the genus Arthrobacter with an antibacterial agent. SOLUTION: This antibacterial agent for oral cavity uses arthrobactin as an active ingredient. The arthrobactin is a material produced by a strain of the genus Arthrobacter sp. no.38 (fermentation research institute deposit no.13198) and is a material of formula I, especially formula II. The antibacterial agent for oral cavity using the arthrobactin as the active ingredient does not destroy a flora in the oral cavity even on administering in a large amount, but manifests specifically high antibacterial activity to Porphyromonas gingivalis. Also in the case of formulated the antibacterial agent to the composition for oral cavity, the formulation amount is approximately 0.0001-10wt.% based on the total amount of the composition for oral cavity.  As the composition for oral cavity, a toothpaste, a liquid state dentifrice, a mouth washing agent, a gergling tablet, a paste for oral cavity, a troche, etc., are cited.
The use of benzodiazepines, including clonazepam, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death (see DRUG ABUSE AND DEPENDENCE: Abuse) .

Before prescribing clonazepam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (e.g., using a standardized screening tool). Use of clonazepam, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of clonazepam along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate.
Autism spectrum disorder (ASD) is a neurodevelopmental disorder that severely affects individuals' daily life and social development. Unfortunately, there are currently no effective treatments for ASD. Dexmedetomidine (DEX) is a selective agonist of α2 adrenergic receptor (α2AR) and is widely used as a first-line medication for sedation and hypnosis in clinical practice. In recent years, there have been reports suggesting its potential positive effects on improving emotional and cognitive functions. However, whether dexmedetomidine has therapeutic effects on the core symptoms of ASD, namely social deficits and repetitive behaviors, remains to be investigated. In the present study, we employed various behavioral tests to assess the phenotypes of animals, including the three-chamber, self-grooming, marble burying, open field, and elevated plus maze. Additionally, electrophysiological recordings, western blotting, qPCR were mainly used to investigate and validate the potential mechanisms underlying the role of dexmedetomidine. We found that intraperitoneal injection of dexmedetomidine in ASD model mice-BTBR T+ Itpr3tf/J (BTBR) mice could adaptively improve their social deficits. Further, we observed a significant reduction in c-Fos positive signals and interleukin-6 (IL-6) expression level in the prelimbic cortex (PrL) of the BTBR mice treated with dexmedetomidine. Enhancing or inhibiting the action of IL-6 directly affects the social behavior of BTBR mice. Mechanistically, we have found that NF-κB p65 is a key pathway regulating IL-6 expression in the PrL region. In addition, we have confirmed that the α2AR acts as a receptor switch mediating the beneficial effects of dexmedetomidine in improving social deficits. This study provides the first evidence of the beneficial effects of dexmedetomidine on core symptoms of ASD and offers a theoretical basis and potential therapeutic approach for the clinical treatment of ASD.
The invention relates to the field of biology, in particular to an anti-CLD18A2 nano antibody. The invention provides an anti-CLD18A2 nanobody, wherein the CDR of the complementarity determining region of the anti-CLD18A2 nanobody comprises the amino acid sequences of CDR 1-CDR 3 as shown in the specification: the amino acid sequence is shown as CDR1 in one of SEQ ID NO. 4-11, the amino acid sequence is shown as CDR2 in one of SEQ ID NO. 19-26, and the amino acid sequence is shown as CDR3 in one of SEQ ID NO. 33-39. The anti-CLD18A2 nano antibody provided by the invention can be specifically combined with the epitope existing on CLD18A2, and the corresponding fusion protein has good specificity and affinity to CLD18A2 and has obvious tumor inhibition effect.
Participants do not receive any intervention during the study. At the end of the study (16 weeks), they are provided with the codes so they can unlock the app and use it like participants from Group 1.
Probiotic VSL#3 will be given at a dose of one capsule thrice daily for 8 weeks, amounting to a total of 337.5 billion CFU/day. Each capsule contains 112.5 billion viable lyophilized bacteria of four strains of Lactobacillus (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734), three strains of Bifidobacterium (B. longum DSM 24736, B. breve DSM 24732, B. infantis DSM 24737) and one strain of Streptococcus (S. thermophilus DSM 24731) and excipients.
The Empathy training consists of five sessions. Each session contains psychoeducation, three-role group exercises, and Q\&A. The interval between every session is 5-14 days. Sessions are scheduled for 1.5 hours, including 30 minutes of psychoeducation, 45 minutes of three-role group exercises, and 15 minutes of Q\&A.
A learning health system and associated methods are provided. Biochemical assays are conducted at scheduled intervals on blood samples taken from an individual to provide, for each of a plurality of biochemical parameters, a time series of values representing the individual. Clinical parameters associated with the individual are extracted from a knowledge base. Genomic parameters are determined for the individual. An expected time series is calculated for each of a plural subset of the plurality of biochemical parameters from at least the clinical parameters and the genomic parameters. For each of the plural subset of biochemical parameters, the time series of values representing the individual is compared to the calculated expected time series to determine a likelihood of each of a plurality of conditions for the individual. The likelihood of at least one of the plurality of conditions is communicated to a user.
Participants who receive contingency management in addition to their usual care (treatment-as-usual). These participants are in the 12-week contingency management program which provides incentives for their treatment attendance.